CVA Family Office LLC Acquires 20 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CVA Family Office LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 21.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 115 shares of the biopharmaceutical company’s stock after acquiring an additional 20 shares during the period. CVA Family Office LLC’s holdings in Regeneron Pharmaceuticals were worth $79,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ronald Blue Trust Inc. raised its stake in shares of Regeneron Pharmaceuticals by 157.9% during the third quarter. Ronald Blue Trust Inc. now owns 49 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 30 shares during the last quarter. SeaCrest Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $40,000. Carolinas Wealth Consulting LLC increased its position in shares of Regeneron Pharmaceuticals by 39.3% during the third quarter. Carolinas Wealth Consulting LLC now owns 78 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 22 shares during the period. Eagle Bay Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $60,000. Finally, Castleview Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 5,459.3% during the second quarter. Castleview Partners LLC now owns 3,280 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 3,221 shares during the period. 84.25% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 1.4 %

Shares of NASDAQ REGN opened at $749.75 on Friday. The firm’s 50 day moving average price is $746.42 and its 200-day moving average price is $727.58. The company has a market cap of $81.97 billion, a PE ratio of 19.61, a P/E/G ratio of 2.59 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 52-week low of $538.01 and a 52-week high of $800.48. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.29 and a current ratio of 5.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last issued its earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.18 by $4.38. The firm had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The business’s revenue was down 31.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $23.72 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 34.22 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Robert E. Landry sold 739 shares of the stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $764.50, for a total transaction of $564,965.50. Following the transaction, the chief financial officer now owns 32,105 shares in the company, valued at $24,544,272.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, insider George Yancopoulos sold 13,189 shares of the stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $800.08, for a total value of $10,552,255.12. Following the transaction, the insider now directly owns 200,504 shares in the company, valued at $160,419,240.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert E. Landry sold 739 shares of the stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $764.50, for a total transaction of $564,965.50. Following the completion of the transaction, the chief financial officer now owns 32,105 shares in the company, valued at $24,544,272.50. The disclosure for this sale can be found here. Insiders have sold a total of 27,273 shares of company stock worth $21,189,979 over the last quarter. Company insiders own 8.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Royal Bank of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $787.00 to $806.00 and gave the company a “sector perform” rating in a research report on Thursday, March 9th. SVB Leerink boosted their price target on shares of Regeneron Pharmaceuticals from $770.00 to $834.00 and gave the company a “market perform” rating in a research report on Monday, February 6th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $1,001.00 to $1,025.00 and gave the company an “outperform” rating in a research report on Tuesday. Robert W. Baird boosted their price target on shares of Regeneron Pharmaceuticals from $670.00 to $756.00 in a research report on Monday, February 6th. Finally, Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $868.00 to $873.00 and gave the company an “overweight” rating in a research report on Tuesday, January 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $815.38.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.